Replimune Group Cash Flow Statement
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.07-0.16 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Replimune Group free cash flow
In fiscal 2026, Replimune Group generated -$280.3 million of operating cash flow and spent $4.2 million on capital expenditures. That left free cash flow of -$284.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Replimune Group cash flow statement (annual)
| Fiscal year (USD) | FY 20262026-03-31 | FY 20252025-03-31 | FY 20242024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20212021-03-31 | FY 20192020-03-31 | FY 20192019-03-31 | FY 20182018-03-31 | FY 20172017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -313.94M | -247.30M | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | 7.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | -355.74% | — |
| Depreciation & Amortization | 3.33M | 3.50M | 2.65M | 2.45M | 2.15M | 1.71M | 533.00K | 148.00K | 109.00K | 122.00K |
| Stock-Based Compensation | 32.27M | 35.04M | 34.13M | 28.13M | 24.25M | 11.79M | 7.74M | 2.73M | 812.00K | 208.00K |
| Change in Working Capital | -5.17M | 9.69M | -4.57M | 922.00K | 303.00K | -2.74M | -2.89M | -681.00K | 1.29M | -122.00K |
| Operating Cash Flow | -280.34M | -192.25M | -185.47M | -128.05M | -82.18M | -61.39M | -60.55M | -25.38M | -16.01M | -7.08M |
| Capital Expenditures | -4.22M | -6.69M | -5.66M | -2.27M | -2.34M | -2.39M | -6.54M | -2.60M | -136.00K | -238.00K |
| Investing Cash Flow | 310.84M | -23.80M | 97.20M | -142.50M | -1.81M | -188.78M | -5.23M | -65.94M | -44.05M | -238.00K |
| Debt Issued | 35.00M | 0 | 15.00M | 28.15M | 0 | — | 10.00M | — | — | — |
| Debt Repaid | — | — | — | — | 0 | -10.00M | — | — | — | — |
| Financing Cash Flow | 66.29M | 252.40M | 16.28M | 311.30M | 6.60M | 372.46M | 100.17M | 101.39M | 54.75M | 15.00M |
| Net Change in Cash | 97.91M | 36.66M | -72.07M | 40.64M | -76.57M | 123.02M | 34.25M | 9.23M | -3.01M | 6.27M |
| Free Cash Flow | -284.57M | -198.94M | -191.13M | -130.32M | -84.52M | -63.78M | -67.09M | -27.98M | -16.15M | -7.32M |
This table shows 10 annual periods of Replimune Group's cash flow statement, from FY 2026 back to FY 2017, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a cash flow statement?